Security
Vertex Pharmaceuticals Incorporated Common Stock · VRTX
VRTXNASDAQCommon stockCurrentCIK 875320Updated Oct 23, 2026
VRTX price & chart
Loading TradingView…
NASDAQ:VRTX on TradingView ↗About the company
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions. The company has approved therapies for cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia and acute pain, and it continues to advance clinical and research programs in these areas. Vertex also has a robust clinical pipeline of investigational therapies across a range of modalities in other serious diseases where it has deep insight into causal human biology, including IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. Vertex was founded in 1989 and has its global headquarters in Boston, with international headquarters in London. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia, Latin America, and the Middle East. Vertex is consistently recognized as one of the industry's top places to work, including 16 consecutive years on Science magazine's Top Employers l…
In the news
Seeking Alpha
Baron Health Care Fund: Q3 2026 New Positions And Exits ↗
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 Transcript ↗
Vertex Pharmaceuticals Incorporated (VRTX) Presents at American Society of Nephrology (ASN) Kidney Week 2026 - Slideshow ↗
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
4 filing
144 filing
10-Q filing
Show 5 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
4 filing
Entry into a Material Definitive Agreement · Regulation FD Disclosure · Other Events
Items 1.01, 7.01, 8.01, 9.01
4 filing
144 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 24,862,300,000Source | 22,240,200,000Source | 27,423,300,000Source | 24,036,700,000Source | 20,132,100,000Source | 26,484,400,000Source | 22,880,500,000Source | 23,917,400,000Source | 25,643,000,000Source | 22,533,200,000Source | 22,730,200,000Source | 18,150,900,000Source |
| GoodwillUSD | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 429,800,000Source | 831,600,000Source | 412,800,000Source | 435,500,000Source | 837,500,000Source | 418,500,000Source | 441,200,000Source | 834,900,000Source | 424,200,000Source | 825,900,000Source | 839,900,000Source | 603,600,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 4,939,600,000Source | 5,239,200,000Source | 6,143,500,000Source | 4,972,200,000Source | 4,580,100,000Source | 5,492,900,000Source | 4,674,700,000Source | 9,158,000,000Source | 5,084,800,000Source | 4,569,600,000Source | 10,369,100,000Source | 10,504,000,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,946,400,000Source | 1,750,600,000Source | 2,134,300,000Source | 1,893,500,000Source | 1,656,100,000Source | 1,996,100,000Source | 1,805,100,000Source | 1,793,200,000Source | 2,052,800,000Source | 1,609,400,000Source | 1,563,400,000Source | 1,442,200,000Source |
| Inventory, NetUSD | 1,626,800,000Source | 1,079,800,000Source | 1,765,100,000Source | 1,499,300,000Source | 914,600,000Source | 1,766,700,000Source | 1,359,700,000Source | 813,100,000Source | 1,686,800,000Source | 1,205,400,000Source | 738,800,000Source | 460,600,000Source |
| Assets, CurrentUSD | 10,569,600,000Source | 9,804,100,000Source | 12,543,700,000Source | 10,427,900,000Source | 8,941,600,000Source | 11,730,300,000Source | 10,008,800,000Source | 13,288,700,000Source | 11,201,000,000Source | 9,596,400,000Source | 14,144,200,000Source | 13,234,800,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 709,400,000Source | 449,200,000Source | 791,900,000Source | 652,300,000Source | 575,400,000Source | 720,800,000Source | 642,800,000Source | 511,100,000Source | 853,300,000Source | 665,700,000Source | 623,700,000Source | 553,500,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,591,800,000Source | 1,396,100,000Source | 1,662,900,000Source | 1,313,800,000Source | 569,800,000Source | 1,685,100,000Source | 1,338,500,000Source | 312,900,000Source | 1,562,700,000Source | 1,356,800,000Source | 293,600,000Source | 347,400,000Source |
| Other Assets, NoncurrentUSD | 1,098,000,000Source | 990,200,000Source | 1,250,900,000Source | 1,078,800,000Source | 915,600,000Source | 1,256,400,000Source | 1,007,300,000Source | 875,700,000Source | 1,236,600,000Source | 999,300,000Source | 895,300,000Source | 521,800,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 7,543,500,000Source | 6,609,300,000Source | 7,175,400,000Source | 6,861,300,000Source | 5,357,400,000Source | 7,122,500,000Source | 6,384,200,000Source | 5,370,800,000Source | 6,977,200,000Source | 6,123,600,000Source | 5,149,800,000Source | 4,238,200,000Source |
| Commitments and ContingenciesUSD | — | 0Source | — | — | 0Source | — | — | 0Source | — | 0Source | 0Source | 0Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, IssuedUSD | 2,500,000Source | 2,600,000Source | 2,500,000Source | 2,600,000Source | 2,600,000Source | 2,500,000Source | 2,600,000Source | 2,600,000Source | 2,500,000Source | 2,600,000Source | 2,600,000Source | 2,600,000Source |
| Retained Earnings (Accumulated Deficit)USD | 12,368,900,000Source | 8,693,800,000Source | 15,691,200,000Source | 11,286,000,000Source | 7,648,400,000Source | 14,591,400,000Source | 10,253,100,000Source | 11,242,000,000Source | 13,560,000,000Source | 9,606,800,000Source | 10,142,400,000Source | 6,522,800,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -64,500,000Source | 28,800,000Source | 48,500,000Source | -101,100,000Source | 22,500,000Source | 24,800,000Source | 68,100,000Source | 17,300,000Source | -15,900,000Source | 127,800,000Source | -14,300,000Source | 800,000Source |
| Stockholders' Equity Attributable to ParentUSD | 17,318,800,000Source | 15,630,900,000Source | 20,247,900,000Source | 17,175,400,000Source | 14,774,700,000Source | 19,361,900,000Source | 16,496,300,000Source | 18,546,600,000Source | 18,665,800,000Source | 16,409,600,000Source | 17,580,400,000Source | 13,912,700,000Source |
| Additional Paid in Capital, Common StockUSD | 5,011,900,000Source | 6,905,700,000Source | 4,505,700,000Source | 5,987,900,000Source | 7,101,200,000Source | 4,743,200,000Source | 6,172,500,000Source | 7,284,700,000Source | 5,119,200,000Source | 6,672,400,000Source | 7,449,700,000Source | 7,386,500,000Source |
| Liabilities and EquityUSD | 24,862,300,000Source | 22,240,200,000Source | 27,423,300,000Source | 24,036,700,000Source | 20,132,100,000Source | 26,484,400,000Source | 22,880,500,000Source | 23,917,400,000Source | 25,643,000,000Source | 22,533,200,000Source | 22,730,200,000Source | 18,150,900,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,475,300,000Source | 3,973,100,000Source | 3,937,900,000Source | 4,138,400,000Source | 3,547,200,000Source | 3,880,600,000Source | 3,783,200,000Source | 3,795,900,000Source | 3,861,200,000Source | 3,564,600,000Source | 3,547,400,000Source | 2,742,100,000Source |
| Operating Lease, Liability, CurrentUSD | — | 66,100,000Source | — | — | — | — | — | — | 77,300,000Source | 87,100,000Source | 33,100,000Source | 48,600,000Source |
| Accounts Payable, CurrentUSD | 420,300,000Source | 395,800,000Source | 429,500,000Source | 442,300,000Source | 327,900,000Source | 489,300,000Source | 445,000,000Source | 351,400,000Source | 461,700,000Source | 413,000,000Source | 364,900,000Source | 303,900,000Source |
| Operating Lease, Liability, NoncurrentUSD | 1,834,800,000Source | 1,588,900,000Source | 1,977,600,000Source | 1,527,400,000Source | 586,800,000Source | 1,986,500,000Source | 1,537,700,000Source | 359,800,000Source | 1,846,500,000Source | 1,544,400,000Source | 348,600,000Source | 379,500,000Source |
| Other Liabilities, NoncurrentUSD | 1,233,400,000Source | 933,300,000Source | 1,259,900,000Source | 1,195,500,000Source | 876,800,000Source | 1,255,400,000Source | 951,900,000Source | 853,600,000Source | 1,269,500,000Source | 901,800,000Source | 877,700,000Source | 685,800,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 3,613,500,000Source | 3,219,700,000Source | 3,179,000,000Source | 3,270,700,000Source | 2,940,000,000Source | 2,984,200,000Source | 2,951,800,000Source | 2,795,900,000Source | 2,971,200,000Source | 2,788,600,000Source | 2,655,300,000Source | 2,126,700,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | 54,000,000Source | 53,200,000Source | 56,500,000Source | 51,700,000Source | 55,900,000Source | 48,400,000Source | 209,800,000Source | 207,200,000Source | 181,300,000Source | 148,300,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 166,400,000Source | 166,100,000Source | 685,900,000Source | 698,500,000Source | 581,200,000Source | 491,300,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -39,800,000Source | 169,600,000Source | 347,300,000Source | 99,300,000Source | 84,100,000Source | 358,600,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 97,700,000Source | 167,100,000Source | 524,200,000Source | 517,300,000Source | 322,900,000Source | 136,400,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 35,600,000Source | 26,200,000Source | 36,800,000Source | 49,500,000Source | 48,700,000Source | 120,800,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -510,800,000Source | -348,800,000Source | -536,500,000Source | -275,900,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 1,428,100,000Source | 818,900,000Source | 3,631,400,000Source | -492,600,000Source | 3,537,300,000Source | 4,129,900,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 295,900,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -431,900,000Source | -55,800,000Source | -945,400,000Source | -3,770,000,000Source | -3,141,700,000Source | -321,100,000Source |
| Payments for (Proceeds from) Other Investing ActivitiesUSD | — | — | — | — | — | — | 0Source | 5,300,000Source | 24,700,000Source | 54,000,000Source | — | — |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 133,400,000Source | 40,700,000Source | 437,600,000Source | 297,700,000Source | 200,400,000Source | 204,700,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 228,500,000Source | 270,500,000Source | 369,900,000Source | 405,000,000Source | 226,100,000Source | 172,000,000Source |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | 336,900,000Source | 426,100,000Source | 2,017,400,000Source | 1,177,100,000Source | 427,600,000Source | 0Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -538,800,000Source | -680,400,000Source | -2,261,300,000Source | -1,494,900,000Source | -562,200,000Source | -67,700,000Source |
| Proceeds from (Payments for) Other Financing ActivitiesUSD | — | — | — | — | — | — | -400,000Source | -500,000Source | 3,700,000Source | 6,200,000Source | — | 3,500,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 417,100,000Source | 113,200,000Source | 515,600,000Source | -5,800,100,000Source | -139,700,000Source | 3,711,900,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 4,947,800,000Source | 5,248,100,000Source | 6,154,100,000Source | 4,982,000,000Source | 5,504,900,000Source | 4,685,400,000Source | 5,087,800,000Source | 4,572,200,000Source | 10,372,300,000Source | 10,512,000,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 3,200,000Source | 2,700,000Source | 12,400,000Source | 30,500,000Source | 43,100,000Source | 52,300,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 82,300,000Source | 184,400,000Source | 1,566,700,000Source | 1,082,100,000Source | 1,677,300,000Source | 1,057,800,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | — | — | — | — | -40,300,000Source | 30,500,000Source | 90,900,000Source | -42,600,000Source | 26,900,000Source | -29,200,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 194,900,000Source | 184,600,000Source | 170,200,000Source | 167,300,000Source | 166,400,000Source | 166,100,000Source | 685,900,000Source | 698,500,000Source | 581,200,000Source | 491,300,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 20,200,000Source | 20,200,000Source | 1,700,000Source | — |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | — | 31,200,000Source | 25,200,000Source | 11,800,000Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 155,800,000Source | 160,400,000Source | 167,800,000Source | 148,300,000Source |
| Equity Securities, FV-NI, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | -15,000,000Source | — | -57,700,000Source | -600,000Source | -149,100,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -13,700,000Source | -27,300,000Source | -24,600,000Source | -15,100,000Source |
| GoodwillUSD | — | — | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source | 1,088,000,000Source |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | 379,000,000Source | 379,000,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | 215,900,000Source | 178,700,000Source | 292,000,000Source | 250,100,000Source | 221,500,000Source | 84,100,000Source | 690,000,000Source | 784,100,000Source | 760,200,000Source | 910,400,000Source |
| InterestExpenseNonoperatingUSD | — | — | 3,300,000Source | 7,500,000Source | — | 3,700,000Source | — | 3,000,000Source | 13,300,000Source | 30,600,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,082,900,000Source | 1,045,400,000Source | 1,099,800,000Source | 1,032,900,000Source | 1,031,400,000Source | 646,300,000Source | 3,953,200,000Source | -535,600,000Source | 3,619,600,000Source | 3,322,000,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -9,800,000Source | -16,900,000Source | 24,300,000Source | 13,200,000Source | 0Source | -17,600,000Source | -7,700,000Source | -86,100,000Source | -22,800,000Source | -164,800,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 55,600,000Source | 50,000,000Source | 80,800,000Source | 144,600,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | 194,900,000Source | 184,600,000Source | 170,200,000Source | 167,300,000Source | 166,400,000Source | 166,100,000Source | 685,900,000Source | 698,500,000Source | 581,200,000Source | 491,300,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | -1,500,000Source | 2,800,000Source | -8,500,000Source | 6,400,000Source | 3,800,000Source | -15,000,000Source | -11,300,000Source | -9,500,000Source | -7,500,000Source | -149,100,000Source |
| Realized Investment Gains (Losses) | — | — | — | — | —Source | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 3,076,400,000Source | 2,771,900,000Source | 3,333,900,000Source | 2,964,700,000Source | 2,986,900,000Source | 2,770,200,000Source | 12,001,300,000Source | 11,020,100,000Source | 9,869,200,000Source | 8,930,700,000Source |
| Cost of RevenueUSD | — | — | 414,800,000Source | 392,600,000Source | 489,200,000Source | 407,500,000Source | 392,800,000Source | 363,000,000Source | 1,651,300,000Source | 1,530,500,000Source | 1,262,200,000Source | 1,080,300,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 445,100,000Source | 371,800,000Source | 582,200,000Source | 424,600,000Source | 493,700,000Source | 396,400,000Source | 1,753,100,000Source | 1,464,300,000Source | 1,136,600,000Source | 944,700,000Source |
| Operating Income (Loss)USD | — | — | 1,186,200,000Source | 1,116,300,000Source | 1,246,900,000Source | 1,151,100,000Source | 1,138,100,000Source | 630,100,000Source | 4,173,300,000Source | -232,900,000Source | 3,832,000,000Source | 4,307,400,000Source |
| Other Nonoperating Income (Expense)USD | — | — | -9,800,000Source | -16,900,000Source | 24,300,000Source | 13,200,000Source | 0Source | -17,600,000Source | -7,700,000Source | -86,100,000Source | -22,800,000Source | -164,800,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 1,298,800,000Source | 1,224,100,000Source | 1,391,800,000Source | 1,283,000,000Source | 1,252,900,000Source | 730,400,000Source | 4,643,200,000Source | 248,500,000Source | 4,379,800,000Source | 4,232,400,000Source |
| Income Tax Expense (Benefit)USD | — | — | 215,900,000Source | 178,700,000Source | 292,000,000Source | 250,100,000Source | 221,500,000Source | 84,100,000Source | 690,000,000Source | 784,100,000Source | 760,200,000Source | 910,400,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,082,900,000Source | 1,045,400,000Source | 1,099,800,000Source | 1,032,900,000Source | 1,031,400,000Source | 646,300,000Source | 3,953,200,000Source | -535,600,000Source | 3,619,600,000Source | 3,322,000,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 4.24Source | 4.05Source | 4.34Source | 4.02Source | 4.06Source | 2.52Source | 15.46Source | -2.08Source | 14.05Source | 12.97Source |
| Earnings Per Share, DilutedUSD per share | — | — | 4.2Source | 4.01Source | 4.31Source | 3.99Source | 4.02Source | 2.49Source | 15.32Source | -2.08Source | 13.89Source | 12.82Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 255,600,000Source | 258,000,000Source | 253,700,000Source | 256,700,000Source | 254,100,000Source | 256,900,000Source | 255,700,000Source | 257,900,000Source | 257,700,000Source | 256,100,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 257,600,000Source | 261,000,000Source | 255,200,000Source | 258,900,000Source | 256,300,000Source | 259,500,000Source | 258,000,000Source | 257,900,000Source | 260,500,000Source | 259,100,000Source |
| Interest Expense (non-operating)USD | — | — | 3,300,000Source | 7,500,000Source | — | 3,700,000Source | — | 3,000,000Source | 13,300,000Source | 30,600,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 20,200,000Source | 20,200,000Source | 1,700,000Source | — |
| Capitalized Computer Software, AmortizationUSD | — | — | — | — | — | — | — | — | 31,200,000Source | 25,200,000Source | 11,800,000Source | — |
| Costs and ExpensesUSD | — | — | 1,890,200,000Source | 1,655,600,000Source | 2,087,000,000Source | 1,813,600,000Source | 1,848,800,000Source | 2,140,100,000Source | 7,828,000,000Source | 11,253,000,000Source | 6,037,200,000Source | 4,623,300,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 1,200,800,000Source | 1,132,900,000Source | 1,296,700,000Source | 1,186,300,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | — | — | — | — | — | — | — | -13,700,000Source | -27,300,000Source | -24,600,000Source | -15,100,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 2,821,200,000Source | -1,369,700,000Source | 3,089,100,000Source | 3,257,000,000Source |
| Interest Income (Expense), NetUSD | — | — | — | — | — | — | — | — | — | — | -44,100,000Source | -54,800,000Source |
| Share-based Payment Arrangement, Expensed and Capitalized, AmountUSD | — | — | 194,900,000Source | 184,600,000Source | 170,200,000Source | 167,300,000Source | 166,400,000Source | 166,100,000Source | 685,900,000Source | 698,500,000Source | 581,200,000Source | 491,300,000Source |
| Investment Income, Net | — | — | — | — | —Source | —Source | —Source | —Source | — | — | — | — |
| Realized Investment Gains (Losses) | — | — | — | — | —Source | — | — | — | — | — | — | — |
Filing attachments
ex-991_q22026.htm · 8-K · 2026-08-03
EX-99.1 2 ex-991_q22026.htm EX-99.1 Document Vertex Reports Second Quarter 2026 Financial Results - Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 - - Raising full-year revenue guidance to $13.1 billion to $13.2 billion - - Continued progress across research and development pipeline; povetacicept PDUFA date November 30th - - Entered into agreement to acquire Crinetics Pharmaceuticals, with closing anticipated in the third quarter of 2026 - BOSTON -- Vert…
Read attachment ↗d113650dex991.htm · 8-K · 2026-07-07
EX-99.1 2 d113650dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 VERTEX PHARMACEUTICALS ACQUISITION OF CRINETICS PHARMACEUTICALS July 6, 2026 Presentation intended for the investment community ©2026 Vertex Pharmaceuticals Incorporated ©2026 Vertex Pharmaceuticals Incorporated Forward-Looking Statements and Non-GAAP Financial Information This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 related to Vertex, Crinetics and t…
Read attachment ↗ex-991_q12026.htm · 8-K · 2026-05-04
EX-99.1 2 ex-991_q12026.htm EX-99.1 Document Vertex Reports First Quarter 2026 Financial Results - Total revenue of $2.99 billion, an 8% increase compared to first quarter 2025 - - Povetacicept program continues rapid advancement: Completed rolling BLA submission for U.S. accelerated approval for povetacicept in IgA nephropathy, following positive Phase 3 interim analysis data; initiated Phase 3 portion of Phase 2/3 study in primary membranous nephropathy and Phase 2 proof-of-concept stud…
Read attachment ↗ex-991_q42025.htm · 8-K · 2026-02-12
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results - Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 - - Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribute $500 million or more in revenue - - Broad mid- and late-stage clinical pipeline accelerates with multiple proof…
Read attachment ↗ex-991_q32025.htm · 8-K · 2025-11-03
EX-99.1 2 ex-991_q32025.htm EX-99.1 Document Vertex Reports Third Quarter 2025 Financial Results - Total revenue of $3.08 billion, an 11% increase compared to Q3 2024 - - Refined full year financial guidance: total revenue guidance now $11.9 to $12.0 billion and total combined non-GAAP R&D, AIPR&D, and SG&A expense guidance now $5.0 to $5.1 billion - - R&D pipeline continues to make progress: five programs in pivotal development and povetacicept Phase 3 IgAN trial full enrollment complet…
Read attachment ↗ex-991_q22025.htm · 8-K · 2025-08-04
EX-99.1 2 ex-991_q22025.htm EX-99.1 Document Vertex Reports Second Quarter 2025 Financial Results - Total revenue of $2.96 billion, a 12% increase compared to Q2 2024; reiterated full year 2025 financial guidance, including revenue guidance of $11.85 to $12 billion - - Continued strong execution of CASGEVY®, ALYFTREK® and JOURNAVX® launches - - Rapid advancement of next wave of clinical programs through pivotal development, with suzetrigine in DPN, zimislecel in T1D, povetacicept in IgAN…
Read attachment ↗